MTX-652 is under clinical development by Mission Therapeutics and currently in Phase I for Chronic Kidney Disease (Chronic Renal Failure). According to GlobalData, Phase I drugs for Chronic Kidney Disease (Chronic Renal Failure) have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MTX-652’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MTX-652 is under development for the treatment of idiopathic pulmonary fibrosis, chronic kidney disease, heart failure and muscular dystrophy. It acts by targeting ubiquitin carboxyl-terminal hydrolase 30 (USP30). The drug candidate is developed based on deubiquitylating enzymes (DUB) screening platform.
Mission Therapeutics overview
Mission Therapeutics (Mission) is a provider of deubiquitylating enzyme drug discovery and development programs. The company develops USP30, USP10 and UHCL1 for patients with mitochondria diseases, neurodegeneration, inflammation and others. the company uses its proprietaryDUB platform to generate small-molecule drug candidates that have clinical and commercial potential.The company receives grants to support the discovery and preclinical development of inhibitors directed against a specific DUB. It operates research facility in Cambridge. Mission is headquartered in Cambridge, the UK.
For a complete picture of MTX-652’s drug-specific PTSR and LoA scores, buy the report here.